



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke

Results From EFFECTS, a Randomized Controlled Trial

Citation for published version:

Lundström, E, Isaksson, E, Greilert Norin, N, Näsman, P, Wester, P, Mårtensson, B, Norrving, B, Wallén, H, Borg, J, Hankey, GJ, Hackett, ML, Mead, G, Dennis, M, Stibrant Sunnerhagen, K & Writing Committee, EFFECTS 2021, 'Effects of Fluoxetine on Outcomes at 12 Months After Acute Stroke: Results From EFFECTS, a Randomized Controlled Trial', *Stroke*. <https://doi.org/10.1161/STROKEAHA.121.034705>

Digital Object Identifier (DOI):

[10.1161/STROKEAHA.121.034705](https://doi.org/10.1161/STROKEAHA.121.034705)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Stroke

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Disclaimer: The manuscript and its contents are confidential, intended for journal review purposes only, and not to be further disclosed.

URL: <https://stroke-submit.aha-journals.org/>

Manuscript Number: STROKE/2021/034705D-AR3

Title: Effects of fluoxetine on outcomes at 12 months after acute stroke. Results from EFFECTS, a randomized controlled trial

Authors:

Erik Lundström (Uppsala university)

Eva Isaksson (Karolinska Institutet)

Nina Greilert Norin (Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet)

Per Näsman (Centre for Safety Research, KTH Royal Institute of Technology)

Per Wester (Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; Department of Clinical Sciences, Danderyd hospital, Stockholm, Sweden)

Björn Mårtensson (Karolinska Institutet)

Bo Norving (Lund University)

Håkan Wallén (Karolinska Institutet)

Jörgen Borg (Karolinska Institutet, Danderyds Hospital)

Graeme Hankey (University of Western Australia)

Maree Hackett (The George Institute for Global Health, Faculty of Medicine, University of New South Wales)

Gillian Mead (University of Edinburgh)

Martin Dennis (University of Edinburgh)

Katharina Stibrant Sunnerhagen (Institute of Neuroscience and Physiology, University of Gothenburg, Sweden)

For

Full title

Effects of fluoxetine on outcomes at 12 months after acute stroke. Results from EFFECTS, a randomized controlled trial

Cover title

Outcome at 12 months in the EFFECTS trial

Erik Lundström, on the behalf of the EFFECTS Writing Committee

Erik Lundström, MD, PhD

Associate Professor, Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden.

Eva Isaksson, RN, PhD

Trial Manager, Department of Clinical Neuroscience, Neurology, Karolinska Institutet, Stockholm, and Department of Neurology, Danderyd Hospital, Stockholm, Sweden.

Nina Greilert Norin, RN

Trial Manager Assistant, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden

Per Näsman, PhD

Title page

Associate Professor, Centre for Safety Research, KTH Royal Institute of Technology,
Stockholm, Sweden

Per Wester, MD, PhD

Professor, Department of Clinical Sciences, Karolinska Institutet, Stockholm and
Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden

Björn Mårtensson, MD, PhD

Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden

Bo Norrving, MD, PhD

Professor, Department of Clinical Sciences, Neurology, Lund University, Lund,
Sweden

Håkan Wallén, MD, PhD

Professor, Department of Clinical Sciences, Karolinska Institutet, Stockholm, Sweden

Jörgen Borg, MD, PhD

Professor emeritus, Department of Clinical Sciences, Karolinska Institutet,
Stockholm, Sweden

Graeme J. Hankey, MD, FRACP

Professor of Neurology, Medical School, Faculty of Health and Medical Sciences,
The University of Western Australia, Perth, Western Australia, Australia.

Consultant Neurologist, Department of Neurology, Sir Charles Gairdner Hospital,
Perth, Western Australia, Australia

Maree L. Hackett, PhD

Title page

Professor, The George Institute for Global Health, Faculty of Medicine,
University of New South Wales Sydney;

Professor of Epidemiology, The University of Central Lancashire, United Kingdom

Gillian E. Mead, MD

Professor of Stroke and Elderly Care Medicine, University of Edinburgh, Royal
Infirmary, Edinburgh, United Kingdom

Martin S. Dennis, MD

Professor of Stroke Medicine, University of Edinburgh, Royal Infirmary, Edinburgh,
United Kingdom

Katharina S. Sunnerhagen, MD, PhD

Professor of Rehabilitation Medicine, Institute of Neuroscience and Physiology-
Clinical Neuroscience, The Sahlgrenska Academy, University of Gothenburg,
Gothenburg, Sweden

Title page

Abstract:	282 words
Text:	1928 words
References:	23
Tables:	2
Figures:	1
Total:	3811
Supplement:	1054 words, 6 Tables

Correspondence to: Erik Lundström. Email: erik.lundstrom@neuro.uu.se.

Social media handler: @lundstrom_erik; @BoNorrving; @MeadGillian; @mareazles;
@gjhankey; @RehabMedGU; @edinburghstroke

Abstract

BACKGROUND AND PURPOSE

The Efficacy of Fluoxetine – a Randomized Controlled Trial in Stroke (EFFECTS) recently reported that 20 mg fluoxetine once daily for 6 months after acute stroke did not improve functional outcome but reduced depression and increased fractures and hyponatremia at 6 months. The purpose of this pre-defined secondary analysis was to identify if any effects of fluoxetine were maintained or delayed over 12 months.

METHODS

EFFECTS was an investigator-led, randomized, placebo-controlled, double-blind, parallel group trial in Sweden that enrolled adult stroke patients. Patients were randomized to 20 mg oral fluoxetine or matching placebo for 6 months and followed for another 6 months. The primary outcome was functional outcome (modified Rankin scale, mRS), at 6 months. Pre-defined secondary outcomes for these analyses included the mRS, health status, quality of life, fatigue, mood and depression at 12 months.

RESULTS

1500 patients were recruited from 35 centers in Sweden between 2014 and 2019; 750 were allocated fluoxetine and 750 placebo. At 12 months, mRS data were available in 715 (95%) patients allocated fluoxetine and 712 (95%) placebo. The distribution of mRS categories was similar in the two groups (adjusted common odds ratio 0.92 [95% CI 0.76–1.10]). Patients allocated fluoxetine scored worse on memory with a median value of 89 (IQR 75–100) vs 93 (IQR 82–100); $p=0.0021$) and communication 93 (IQR 82–100) vs 96 (IQR 86–100); $p=0.024$) domains of the Stroke Impact Scale compared to placebo. There were no other differences in secondary outcomes.

CONCLUSIONS

Fluoxetine after acute stroke had no effect on functional outcome at 12 months. Patients allocated fluoxetine scored worse on memory and communication on the Stroke Impact Scale compared to placebo, but this is likely to be due to chance.

CLINICAL TRIAL REGISTRATIONS

The EU Clinical Trials Register <https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-006130-16>.

ClinicalTrials.gov NCT02683213. <https://clinicaltrials.gov/ct2/show/NCT02683213>.

Non-standard Abbreviations and Acronyms

AFFINITY	Assessment of Fluoxetine in Stroke recovery trial
EFFECTS	Efficacy of Fluoxetine – a randomised Controlled Trial in Stroke
EQ-5D-5L	The 5-level EQ-5D version
FLAME	Fluoxetine for motor recovery After acute ischaemic stroke trial
FOCUS	Fluoxetine Or Control Under Supervision trial
MHI-5	Mental Health Inventory-5
N06A	The Anatomical Therapeutic Chemical (ATC) code for antidepressant drugs. N06A includes N06AA, N06AB, N06AF, N06AG, and N06AX.
RCT	Randomized controlled trial
SIS	Stroke Impact Scale version 3.0
SSRI	Selective serotonin re-uptake inhibitor
mRS	Modified Rankin Scale
SF-36	36-Item Short Form Health Survey

In 2011, the FLuoxetine for motor recovery After acute ischeMic strokeE (FLAME) trial reported that fluoxetine enhanced motor recovery after acute ischemic stroke.¹ A Cochrane systematic review of 4059 patients included in 52 randomized controlled trials (RCTs) of selective serotonin re-uptake inhibitors (SSRIs) for stroke recovery concluded that SSRIs could reduce disability but in the light of the methodological limitations and heterogeneity of the trials, more data were needed.² In 2020, the Efficacy of Fluoxetine – a randomisEd Controlled Trial in Stroke (EFFECTS) authors reported that 20 mg of fluoxetine once daily for 6 months after acute stroke did not improve functional outcome at 6 months compared to placebo, although the occurrence of depression was reduced and fractures and hyponatremia increased.³ EFFECTS included 1500 stroke patients from Sweden, and the results were similar to those of two other large RCTs with comparable design.^{4,5}

As specified in the protocol^{6,7} and statistical analysis plan⁸ we followed-up participants to 12 months, to examine whether any effects of fluoxetine identified at 6 months were sustained or delayed.

Methods

The anonymized data that support the findings of this trial are available to other researchers from the corresponding author (EL) upon reasonable request following receipt of a written application and proposal for use of the data, approval by the EFFECTS trial Steering Committee, and establishment of a data sharing agreement.

The design, methods and primary results of the EFFECTS trial have been published.^{3,6-8} Briefly, EFFECTS was a randomized, double-blind, placebo-controlled clinical trial conducted in 35 hospital stroke units in Sweden. The trial was approved by a central medical ethics committee in Stockholm (reference 2013/1265-31/2) and by the Swedish Medical

Agency (reference 5.1-2014-43006); all patients provided written informed consent. EFFECTS was registered in the EU Clinical Trials Register (number 2011-006130-16; start date 8 Aug 2014) and ClinicalTrials.gov (NCT02683213; 17 Feb, 2017). We have followed the CONSORT statement.⁹

Eligible patients were adults (aged ≥ 18 years) with a clinical diagnosis of acute stroke within the previous 2-15 days, brain imaging consistent with ischemic or hemorrhagic stroke, and a persisting neurological deficit at the time of randomization. Patients were excluded if they were depressed or taking antidepressants; had a contraindication to fluoxetine; were unlikely to be available for follow-up during the subsequent 12 months; had another life-threatening illness that would make 12-month survival unlikely; were enrolled in another clinical trial of an investigational medicinal product or device; and women were excluded if pregnant, breast-feeding or of child-bearing age and not using contraception. Baseline characteristics and outcome at 6 months are available in Data Supplement (Table I–III).

Randomization was via a secure, centralized, web-based system which used a minimization algorithm³ and assigned patients to fluoxetine or placebo in a 1:1 ratio. Placebo capsules were visually identical to the fluoxetine capsules even when broken open. Fluoxetine 20 mg capsules or matching placebo capsules were administered orally once daily for 6 months.

Patients were followed-up at 6 and 12 months by postal questionnaire or telephone by one research nurse (NGN) in the trial coordinating center at Danderyd Hospital. If the patient was unable to complete the questionnaire, assistance was sought from their next of kin or carer. In this paper we report the following predefined secondary outcomes at 12 months:

- Functional status, measured with the modified Rankin Scale (mRS).¹⁰ We used the simple mRS questionnaire^{11–13} to derive the mRS score.

- Health status using the Stroke Impact Scale version 3.0 (SIS).¹⁴ The SIS is a 59-item self-reported questionnaire that includes 8 domains: arm, hand, leg, and foot strength; hand function; mobility; communication and understanding; memory and thinking; mood and emotions; daily activities; and participation in work, leisure, and social activities. Four of the subscales (strength, hand function, daily activities, and mobility) can be combined into a composite physical domain. Scores for each domain range from 0 to 100, and higher scores indicate better health. The SIS also contains a question to assess the patient's global experience of recovery. The patient is asked to score their recovery on a visual analog scale ranging from 0-100, with 0 meaning no recovery and 100 meaning full recovery.
- Depression, defined as taking an antidepressant medication (Anatomical Therapeutic Chemical code beginning with N06A) at 12 months.
- Mood, using the Mental Health Inventory 5 (MHI-5) scale¹⁵. The MHI-5 is a subscale of the 36-Item Short Form Health Survey (SF-36)¹⁶ containing 5 questions, each with 6 possible answers, with a score of 1-6; possible sum of scores ranges from 5-30. The total score is transformed into a value between 0-100, where 100 represents optimal mental health. A value below 60 has been suggested as moderate-to-poor mental health.¹⁷
- Fatigue, using the vitality subscale¹⁸ of the SF-36. Four questions, each with 5 answers scored from 1 to 5 (sum ranges from 4-20). The sum score is transformed to a value between 0-100. Scores below 50 indicate fatigue.¹⁹
- Health-related quality of life, measured with the EQ-5D-5L²⁰. EQ-5D-5L includes 5 dimensions: mobility; personal care; usual activities; pain/discomfort; and anxiety/depression. We calculated an EQ-5D index – where 1 indicates the best health

imaginable, and 0 indicates the worst health imaginable – using the UK cross-walk value set, since it is the most commonly used.²¹

The participant, care provider, investigator, and outcomes assessor remained masked to the allocated trial treatment until the 12 month assessment.

Except death, we did not collect any adverse event or safety outcome data between 6 and 12 months. Long-term follow-up is planned to at least 3 years using central registries.

Statistical analysis

We published the statistical analysis plan before recruitment was completed and without awareness of any unmasked data.⁸

The primary outcome for this report, the mRS scores at 12 months, were analyzed using ordinal logistic regression before and after adjusting for the baseline factors included in the minimization algorithm.³ We used the following co-variables in the algorithm: days between stroke and randomization; probability of being alive and independent at 6 months; motor deficit; and aphasia. We presented the results as an adjusted and a non-adjusted common Odds Ratio (OR) where a number below 1.0 indicates that placebo is better than fluoxetine, with a 95% confidence interval (CI).

The secondary outcomes were compared (unadjusted) using Mann-Whitney *U* test. For continuous secondary outcomes, the mean or median in each group was calculated with standard deviation or inter-quartile range, depending on the distribution. The probability that outcomes in the fluoxetine group were significantly different from the placebo group were calculated as p-values (2-sided).

All analyses were by intention-to-treat, and were carried out in SAS for Windows, Software 9.4, SAS Institute Inc., Cary, NC, USA.

Results

EFFECTS recruitment started 20th Oct 2014 and ended 28th June 2019; 750 were assigned to fluoxetine and 750 to placebo. Last 12 months follow-up was 8th July 2020. Baseline characteristics were well balanced, 87.4% had ischemic stroke, 12.3% had intracerebral hemorrhage, 0.2% had non-stroke. The mean age was 71 years (SD 11), 38.3% were women, 96.3% were previously independent, and the median NIHSS score was 3.³ For both groups, the median duration of treatment was 180 days (IQR 180-180). Most patients (1338/1500, 89%) took the trial medication for at least 150 days.³

At 12 months, mRS data were available for 715 (95%) patients in the fluoxetine group and 712 (95%) patients in the placebo group (Figure 1). No patients withdrew consent for follow-up between 6 and 12 months; 4.1% (62/1500) were lost to follow-up at 12 months, and 4.5% (68/1500) died within 12 months (Supplemental Table IV).

Table 1 shows the mRS¹⁰ scores 12 months after randomization, i.e. 6 months after cessation of trial medication. There was no difference in the distribution across mRS categories in the fluoxetine and placebo groups (adjusted common OR 0.92 [95% CI 0.76-1.10]). The unadjusted analysis produced similar results (common OR 0.96 [95% CI 0.80-1.15]; Table 1).

Table 2 shows the secondary outcomes in the fluoxetine and placebo groups. Patients randomized to fluoxetine had significantly worse values on the memory [median value of 89 (IQR 75-100) vs 93 (IQR 82-100); p=0.0021] and communication [93 (IQR 82-100) vs 96 (IQR 86-100); p=0.024] domains of the Stroke Impact Scale v3 compared to placebo. There were no other differences on the secondary outcomes (Table 2).

Six months after randomization, 5.8% (87/1500) of the patients reported that they were taking an open-label antidepressant; 4.8% (36/750) had been randomized to fluoxetine, and 6.8% (51/750) to placebo.⁴

At 12 months follow-up, 8.8% of the survivors from 6 months (129/1453) were taking an open-label antidepressant; 9.0% (65/725) randomized to fluoxetine, and 8.8% (64/728) to placebo (diff 0.2%, 95% CI -3.1-3.8) (Supplemental Table V and Supplemental Table VI). Of patients on an antidepressant at 6 months, 60% (51/87) patients continued to take antidepressant at 12 months follow-up; 41% (21/36) randomized to fluoxetine, and 59% (30/51) to placebo.

Discussion

The results of the EFFECTS trial show that fluoxetine 20 mg daily for 6 months after acute stroke had no effect on functional outcome up to 1 year after stroke. Similar results have been found in the FOCUS⁵ (n=3124, UK), and AFFINITY⁴ (n=1260, Australia, New Zealand and Vietnam) trials.

Although fluoxetine reduced depression by approximately 4% (from 11% to 7%) at 6 months in EFFECTS, the proportion of patients on an antidepressant was similar for the two groups at 12 months (9%). Depression is an episodic disorder for most, and not being on antidepressant right at the 12 months assessment does not exclude they did not take one between 6 and 11 months; we cannot rule out that some patients were successfully treated already and drug not needed. Compared to our 6-month follow-up, no clinical evaluation of depression symptoms was performed at 12 months. In a meta-analysis of observational studies, the pooled frequency of depression 6 to 12 months post stroke was 31% and 33%, respectively²², more than three times higher than the observed proportion in EFFECTS. One possible explanation

might be that EFFECTS included patients with relatively mild stroke. Another explanation might be that patients showing symptoms of depression before study start were not included.

Our finding of better reported memory and communication for patients in the placebo group compared with those allocated to the fluoxetine group is unexpected and not supported by the results in FOCUS and AFFINITY. We view this result as a chance finding due to random error associated with multiple analyses.

Our study has several limitations. First, we did not routinely collect data on safety after 6 months, except death. Reassuringly, there was no difference between the groups in death, and we plan to follow the patients for at least 3 years via central registries in Sweden, to collect data on depression, fractures and epilepsy. Second, we did not monitor the level and intensity of rehabilitation between 6 and 12 months. Third, our definition of depression as ‘a patient on an antidepressant drug’ is crude, probably underestimating the true occurrence, and it would have been better to evaluate depression face-to-face, as we did at 6 months. Nonetheless, defining depression – not the least in the context of brain damage, is difficult – which is reflected in the varied incidence in the literature.²²

Our result is probably generalizable to high-income countries with a similar healthcare structure.

In conclusion, fluoxetine 20 mg once daily for six months after acute stroke had no effect on functional outcome at 12 months. Patients allocated fluoxetine scored worse on memory and communication on the Stroke Impact Scale compared to placebo, but this is likely to be due to chance. More precise estimates of any effects of fluoxetine will be available from our prospective meta-analysis of individual patient data from the FOCUS, AFFINITY and EFFECTS trials.²³

Acknowledgements

We thank all patients in the EFFECTS trial, personnel in the EFFECTS Trial Collaboration, Chief Technical Officer Krister Kristianson at EDC Scandinavia, and our monitors Terése Brunsell, Maria Persson, and Ingalill Reinholdsson, at Karolinska Trial Alliance.

Sources of funding and sponsor

EFFECTS has received funding from the Swedish Research Council (registration number 2014-07072); the Swedish Heart-Lung Foundation (application number 2013-0496 and 2016-0245); the Swedish Brain Foundation (application number FO2017-0115); the Swedish Society of Medicine (ID 692921); King Gustav V and Queen Victoria's Foundation of Freemasons (year 2014); and the Swedish Stroke Association (STROKE-Riksförbundet; year 2012 and 2013).

The funders of the trial had no role in trial design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the trial and had final responsibility for the decision to submit for publication.

The sponsor was Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, 182 88 Stockholm, Sweden.

The sponsor's representative was EL.

Disclosures

Prof. Hankey reports grants from the National Health & Medical Research Council of Australia, Vetenskapsrådet (The Swedish Research Council), and United Kingdom National Institute for Health Research Technology (NIHR), during the conduct of the trial; and personal fees from American Heart Association, outside the submitted work.

Prof. Hackett, Mead, and Dennis report grants from National Health and Medical Research Council of Australia, Vetenskapsrådet (The Swedish Research Council), and United Kingdom National Institute for Health Research Technology (NIHR), during the conduct of the trial.

Supplemental material

Table I–VI

References

1. Chollet F, Tardy J, Albucher J-F, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *The Lancet Neurology*. 2011;10:123–130.
2. Mead GE, Hsieh C-F, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, Hackett ML. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery [Internet]. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 2012 [cited 2021 Jun 2]. Available from: <https://doi.org/10.1002/14651858.CD009286.pub2>.
3. Lundström E, Isaksson E, Näsman P, Wester P, Mårtensson B, Norrving B, Wallén H, Borg J, Dennis M, Mead GE, et al. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2020;19:661–669.
4. AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol*. 2020;19:651–660.
5. Dennis M, Mead G, Forbes J, Graham C, Hackett M, Hankey GJ, House A, Lewis S, Lundström E, Sandercock P, et al. Effects of fluoxetine on functional outcomes after acute

- stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. *The Lancet*. 2019;393:265–274.
6. Mead G, Hackett ML, Lundström E, Murray V, Hankey GJ, Dennis M. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials. *Trials*. 2015;16:369.
 7. Lundström E, Isaksson E, Näsman P, Wester P, Mårtensson B, Norrving B, Wallén H, Borg J, Dennis M, Mead G, et al. Update on the EFFECTS study of fluoxetine for stroke recovery: a randomised controlled trial in Sweden. *Trials*. 2020;21:233.
 8. Graham C, Lewis S, Forbes J, Mead G, Hackett ML, Hankey GJ, Gommans J, Nguyen HT, Lundström E, Isaksson E, et al. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. *Trials*. 2017;18:627.
 9. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c332.
 10. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V. Measurements of acute cerebral infarction: a clinical examination scale. *Stroke*. 1989;20:864–870.
 11. Bruno A, Akinwuntan AE, Lin C, Close B, Davis K, Baute V, Aryal T, Brooks D, Hess DC, Switzer JA, et al. Simplified modified rankin scale questionnaire: reproducibility over the telephone and validation with quality of life. *Stroke*. 2011;42:2276–2279.
 12. Dennis M, Mead G, Doubal F, Graham C. Determining the modified Rankin score after stroke by postal and telephone questionnaires. *Stroke*. 2012;43:851–853.
 13. Isaksson E, Wester P, Laska AC, Näsman P, Lundström E. Validation of the Simplified Modified Rankin Scale Questionnaire. *Eur Neurol*. 2020;1–7.

14. Duncan PW, Reker DM, Horner RD, Samsa GP, Hoenig H, LaClair BJ, Dudley TK. Performance of a mail-administered version of a stroke-specific outcome measure, the Stroke Impact Scale. *Clin Rehabil.* 2002;16:493–505.
15. Hoeymans N, Garssen AA, Westert GP, Verhaak PFM. Measuring mental health of the Dutch population: a comparison of the GHQ-12 and the MHI-5. *Health Qual Life Outcomes.* 2004;2:23.
16. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care.* 1992;30:473–483.
17. Kelly MJ, Dunstan FD, Lloyd K, Fone DL. Evaluating cutpoints for the MHI-5 and MCS using the GHQ-12: a comparison of five different methods. *BMC Psychiatry.* 2008;8:10.
18. Mead G, Lynch J, Greig C, Young A, Lewis S, Sharpe M. Evaluation of fatigue scales in stroke patients. *Stroke.* 2007;38:2090–2095.
19. Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke : results from the Auckland Stroke Study, 1991-1992. *Stroke.* 2000;31:440–447.
20. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res.* 2011;20:1727–1736.
21. van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value Sets. *Value in Health.* 2012;15:708–715.
22. Hackett ML, Pickles K. Part I: Frequency of Depression after Stroke: An Updated Systematic Review and Meta-Analysis of Observational Studies. *International Journal of Stroke.* 2014;9:1017–1025.

23. Mead GE, Graham C, Billot L, Näsman P, Lundström E, Lewis S, Hankey GJ, Hackett ML, Forbes J, Dennis M, et al. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. *Trials*. 2020;21:971.

For Stroke Peer Review. Do not distribute. Destroy
after use.

Figure Legends

Figure 1.

CONSORT Flow diagram

* Two patients (one in each group) withdrew their consent regarding face-to-face follow-up, however, they both agreed to answer the questionnaire at 12 months.

mRS = modified Rankin Scale

For Stroke Peer Review. Do not distribute. Destroy after use.

Table 1. Modified Rankin Scale¹⁰ score 6 and 12 months after randomization. Data at 6 months have previously been published.³

Modified Rankin Scale		6 months		12 months	
		Fluoxetine n=737	Placebo n=742	Fluoxetine n=715	Placebo n=712
0	No symptoms	156 (21)	170 (23)	160 (22)	178 (25)
1	No clinically significant disability despite symptoms	216 (29)	199 (27)	224 (31)	201 (28)
2	Slightly disability: unable to do everything	94 (13)	106 (14)	75 (11)	88 (12)
3	Moderately disability: unable to live independently but can walk	168 (23)	164 (22)	158 (22)	141 (20)
4	Moderately disability and unable to walk without help from another person	46 (6)	48 (7)	35 (5)	42 (6)
5	Severe disability: unable to sit up	32 (4)	33 (4)	29 (4)	28 (4)
6	Dead	25 (3)	22 (3)	34 (5)	34 (5)

Data are n (%)

Adjusted odds ratio at 6 months: 0.94 (95% Confidence Interval [CI] 0.78–1.13).

Common odds ratio at 6 months: 0.97 (95% CI 0.81–1.16).

Adjusted odds ratio at 12 months: 0.92 (95% CI 0.76–1.10).

Common odds ratio at 12 months: 0.96 (95% CI 0.80–1.15).

Table 2. Secondary outcomes at 6 and 12 months by allocated treatment group. Data on Stroke Impact Scale at 6 months have previously been published.³

	Fluoxetine (n=750) at 6 months			Placebo (n=750) at 6 months			P-value**	Fluoxetine (n=642) at 12 months follow-up			Placebo (n=638) at 12 months follow-up			P value**
	N*	Median	IQR	N*	Median	IQR		N*	Median	IQR	N*	Median	IQR	
Stroke Impact Scale version 3.0¹⁴ domains														
Strength	694	75	(50–94)	689	75	(50–94)	0.67	662	75	(50–94)	658	75	(50–94)	0.88
Hand ability	690	81	(50–100)	692	88	(50–100)	0.99	664	81	(56–100)	661	81	(50–100)	0.75
Mobility	696	89	(72–100)	698	89	(72–97)	1.00	665	89	(69–100)	662	89	(72–100)	0.84
Motor†	697	80	(60–93)	695	81	(58–94)	0.95	665	79	(60–94)	661	80	(58–94)	0.88
Daily Activities	697	88	(69–98)	697	88	(68–98)	0.72	667	90	(70–98)	662	90	(68–98)	0.97
Physical function‡	697	77	(56–90)	697	77	(56–91)	0.81	667	76	(57–91)	662	77	(55–92)	0.98
Memory	696	89	(79–100)	698	93	(82–100)	0.0064	666	89	(75–100)	662	93	(82–100)	0.0021
Communication	695	96	(82–100)	697	92	(86–100)	0.83	664	93	(82–100)	661	96	(86–100)	0.024

	Fluoxetine (n=750) at 6 months			Placebo (n=750) at 6 months			P-value**	Fluoxetine (n=642) at 12 months follow-up			Placebo (n=638) at 12 months follow-up			P value**
	N*	Median	IQR	N*	Median	IQR		N*	Median	IQR	N*	Median	IQR	
Mood and emotional control	695	81	(67–92)	696	76	(64–89)	0.0002	665	78	(64–89)	658	78	(64–89)	0.63
Participation	690	66	(46–89)	682	69	(44–89)	0.55	663	69	(46–91)	656	71	(47–93)	0.79
Recovery (VAS)	695	70	(50–90)	695	70	(50–90)	0.79	666	75	(50–90)	662	80	(50–90)	0.58
Fatigue ¹⁸	692	56	(44–69)	692	56	(44–69)	0.74	662	56	(44–75)	658	56	(44–75)	0.22
MHI-5 score ¹⁵	697	76	(64–88)	695	72	(60–88)	0.0086	667	76	(60–88)	660	76	(60–88)	0.57
EQ-5D-5L ²⁰	687	0.73	(0.55–0.84)	684	0.71	(0.54–0.84)	0.83	664	0.74	(0.55–0.84)	658	0.74	(0.55–0.88)	0.86

* The number of patients with each of the secondary outcome scores. Data were only available for those who survived and who completed sufficient questions to derive a score.

** Mann-Whitney *U* test, between fluoxetine and placebo at 6 and 12 months, respectively.

Stroke Impact Scale v 3.0¹⁴ is a patient-reported design to assess stroke outcome, where higher scores are better.

†Mean of the Strength, Hand ability, and Mobility domains.

‡Mean of the Strength, Hand ability, Mobility, and Daily activities domains.

VAS = visual analogue scale.

Fatigue¹⁸ was measured with the vitality sub-scale of the SF-36 questionnaire. Higher scores indicate more energy, less fatigue.

MHI-5¹⁵ = Mental Health Inventory-5.

EQ-5D-5L²⁰ = The 5-level EQ-5D version. The EQ-5D-5L has 5 dimensions: mobility; personal care; usual activities; pain/discomfort; and anxiety/depression. We calculated an EQ-5D index using the UK cross-walk value, where 1 indicates the best health imaginable, and 0 indicates the worst health imaginable.

Contributors

EL was the Chief Investigator, was involved in the design of the trial, collected, verified, and analysed data, and wrote first draft of the manuscript.

EI was the Trial Manager, was involved in the design of the trial, and collected, verified, analysed data.

NGN was the Trial Manager assistant, collected, verified and analysed data.

PN was involved in the design of the trial, did the statistical analysis, and analysed data.

BM advised on the management of depression within the trial and was involved in the design of the trial.

PW, BN, HW, JB, GJH, MLH, GM, MD and KSS were involved in the design of the trial, and analysed data. All contributors have commented on the analyses and drafts and seen and approved the final version of the manuscript.

